Blastic Leukaemias (AML): A Biologist's View

Cell Biochemistry and Biophysics

Volumn 66, Issue 1, 2013, Pages 13-22

  Cáceres Cortés, Julio Roberto ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

AML; Apoptosis; Autophagy; Cancer stem cells

Indexed keywords

EID: 84876174189     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-012-9392-8     Document Type: Article

References (65)

1. Estey, E., & Döhner, H. (2006). Acute myeloid leukaemia. Lancet, 368, 1894-1907.
2. Tefferi, A. (2008). JAK and MPL mutations in myeloid malignancies. Leukaemia & Lymphoma, 49, 388-397.
3. Catenacci, D. V., & Schiller, G. J. (2005). Myelodysplasic syndromes: a comprehensive review. Blood Reviews, 19, 301-319.
4. Linet, M. S., Devesa, S. S. (1991). Descriptive epidemiology of the leukemias. In E. S. Henderson, T. A. Lister, (Eds), Leukemia, 5th edn. Cancer facts and figures-1991 (pp. 1-31). Atlanta: American Cancer Society Inc.
5. Wiernik, P. H. (1989). Acute leukemias. In V. T. DeVita, S. Hellman, & S. A. Rosenberg (Eds.), Cancer: principles and practice of oncology (3rd ed., pp. 1809-1835). Philadelphia: JB Lippincott Company.
6. Howlader, N., Noone, A. M., Krapcho, M., Neyman, N., Aminou, R., Altekruse, S. F., et al. (Eds.). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute. http://seer. cancer. gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
7. Ruiz-Argüelles, G. J., Garcés-Eisele, J., Reyes-Núñez, V., Gómez-Rangel, J. D., & Ruiz-Delgado, G. J. (2004). More on geographic hematology: the breakpoint cluster regions of the PML/RARalpha fusion gene in Mexican Mestizo patients with promyelocytic leukemia are different from those in Caucasians. Leukaemia & Lymphoma, 45, 1365-1368.
8. Kumar, C. C. (2011). Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer, 2, 95-107.
9. Brunning, R. D. (2003). Classification of acute leukemias. Seminars in Diagnostic Pathology, 20, 142-153.
10. Falini, B., Tiacci, E., Martelli, M. P., Ascani, S., & Pileri, S. A. (2010). New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues. Discovery Medicine, 10, 281-292.
11. Blair, A., Hogge, D. E., & Sutherland, H. J. (1998). Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-. Blood, 92, 4325-4335.
12. Moore, C. V. (1964). Natural history and diagnostic peculiarities of acute leukemia. CA: A Cancer Journal for Clinicians, 14, 204-209. eliminar.
13. Russell, N. H. (1992). Autocrine growth factors and leukaemic haemopoiesis. Blood Reviews, 6, 149-156.
14. Forman, S. J. (2009). What is the role of reduced-intensity transplantation in the treatment of older patients with AML? Hematology: The Education Program of the American Society of Hematology, 2009, 406-413.
15. Metcalf, D. (2010). The colony-stimulating factors and cancer. Nature Reviews Cancer, 10, 425-434.
16. Lawler, M., Locasciulli, A., Longoni, D., Schiro, R., & McCann, S. R. (2002). Leukaemic transformation of donor cells in a patient receiving a second allogeneic bone marrow transplant for severe aplastic anaemia. Bone Marrow Transplantation, 29, 453-456.
17. McCulloch, E. A., Minkin, S., Curtis, J. E., & Minden, M. D. (1996). Response of the blast stem cells of acute myeloblastic leukemia to G-CSF, GM-CSF, or the ligand for C-KIT, alone or in combination. Hematopathology and Molecular Hematology, 10, 111-122.
18. Cáceres-Cortés, J. R., & Hoang, T. (1992). Product of the Steel locus can replace leukemic cell interaction. Cancer Research, 52, 5208-5212.
19. Caceres-Cortes, J. R., Alvarado-Moreno, J. A., Waga, K., Rangel-Corona, R., Monroy-Garcia, A., Rocha-Zavaleta, L., et al. (2001). Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemias. Cancer Research, 61, 6281-6289.
20. Broudy, V. C., Smith, F. O., Lin, N., Zsebo, K. M., Egrie, J., & Bernstein, I. D. (1992). Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. Blood, 80, 60-67.
21. Hassan, H. T., & Zander, A. (1996). Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Acta Haematologica, 95, 257-262.
22. Zheng, R., Klang, K., Gorin, N. C., & Small, D. (2004). Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML. Leukemia Research, 28, 121-126. Erratum in: Leukemia Research 2004; 28, 1241.
23. Greenberger, J. S. (1989). Ras mutations in human leukemia and related disorders. International Journal of Cell Cloning, 7, 343-359.
24. Malaise, M., Steinbach, D., & Corbacioglu, S. (2009). Clinical implications of c-Kit mutations in acute myelogenous leukemia. Current Hematologic Malignancy Reports, 4, 77-82.
25. Levitzki, A., & Mishani, E. (2006). Tyrphostins and other tyrosine kinase inhibitors. Annual Review of Biochemistry, 75, 93-109.
26. Caceres-Cortes, J. R. (2008). A potent anti-carcinoma and anti-acute myeloblastic leukemia agent, AG490. Anticancer Agents in Medicinal Chemistry, 8, 717-722.
27. Lara-Padilla, E., & Caceres-Cortes, J. R. (2012). On the nature of the tumor-initiating cell. Current Stem Cell Research and Therapy, 7, 26-35.
28. Lopes de Menezes, D. E., Peng, J., Garrett, E. N., Louie, S. G., Lee, S. H., Wiesmann, M., et al. (2005). CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clinical Cancer Research, 11, 5281-5291.
29. Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000). Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood, 96, 925-932.
30. Kubo, K., Shimizu, T., Ohyama, S., Murooka, H., Iwai, A., Nakamura, K., et al. (2005). Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. Journal of Medicinal Chemistry, 48, 1359-1366.
31. Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., et al. (2009). Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One, 4(9), e7258.
32. Mahadevan, D., Cooke, L., Riley, C., Swart, R., Simons, B., Della Croce, K., et al. (2007). A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene, 26, 3909-3919.
33. Garton, A. J., Crew, A. P., Franklin, M., Cooke, A. R., Wynne, G. M., Castaldo, L., et al. (2006). OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Research, 66, 1015-1024.
34. Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., et al. (2011). Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. International Journal of Cancer, 129, 245-255.
35. Eskens, F. A., Steeghs, N., Verweij, J., Bloem, J. L., Christensen, O., van Doorn, L., et al. (2009). Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. Journal of Clinical Oncology, 27, 4169-4176.
36. Visvader, J. E. (2011). Cells of origin in cancer. Nature, 469, 314-322.
37. Tan, B. T., Park, C. Y., Ailles, L. E., & Weissman, I. L. (2006). The cancer stem cell hypothesis: a work in progress. Laboratory Investigation, 86, 1203-1207.
38. Killmann, S. A. (1976). Preleukemia: does it exist? Nouvelle Revue Française d'Hématologie; Blood Cells, 17, 81-105.
39. Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645-648.
40. Dick, J. E., & Lapidot, T. (2005). Biology of normal and acute myeloid leukemia stem cells. International Journal of Hematology, 82, 389-396.
41. Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3, 730-737.
42. Soltysova, A., Altanerova, V., & Altaner, C. (2005). Cancer stem cells. Neoplasma, 52, 435-440.
43. Setoguchi, T., Taga, T., & Kondo, T. (2004). Cancer stem cells persist in cancer cell lines. Cell Cycle, 3, 414-415.
44. Liang, C., Feng, P., Ku, B., Dotan, I., Canaani, D., Oh, B. H., et al. (2006). Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nature Cell Biology, 8, 688-699.
45. Watson, A. S., Mortensen, M., & Simon, A. K. (2011). Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia. Cell Cycle, 10, 1719-1725.
46. Yecies, J. L., & Manning, B. D. (2011). mTOR links oncogenic signaling to tumor cell metabolism. Journal of Molecular Medicine (Berlin, Germany), 89, 221-228.
47. Chiacchiera, F., & Simone, C. (2009). Signal-dependent control of autophagy-related gene expression. Methods in Enzymology, 453, 305-324.
48. Katayama, M., Kawaguchi, T., Berger, M. S., & Pieper, R. O. (2007). DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death and Differentiation, 14, 548-558.
49. Abedin, M. J., Wang, D., McDonnell, M. A., Lehmann, U., & Kelekar, A. (2007). Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death and Differentiation, 14, 500-510.
50. Zhang, M., & Rosen, J. M. (2006). Stem cells in the etiology and treatment of cancer. Current Opinion in Genetics & Development, 16, 60-64.
51. Reed, J. C. (2004). Apoptosis mechanisms: implications for cancer drug discovery. Oncology (Williston Park), 18, 11-20.
52. Buytaert, E., Callewaert, G., Vandenheede, J. R., & Agostinis, P. (2006). Deficiency in apoptotic effectors Bax and Bak reveals an autophagic cell death pathway initiated by photodamage to the endoplasmic reticulum. Autophagy, 2, 238-240.
53. Rushworth, S. A., Murray, M. Y., Barrera, L. N., Heasman, S. A., Zaitseva, L., & Macewan, D. J. (2012). Understanding the role of miRNA in regulating NF-κB in blood cancer. American Journal of Cancer Research, 2, 65-74.
54. Singer, B. H., & Pincus, S. (1998). Irregular arrays and randomization. Proceedings of the National Academy of Sciences of the United States of America, 95, 1363-1368.
55. Voog, J., & Jones, D. L. (2010). Stem cells and the niche: a dynamic duo. Cell Stem Cell, 6, 103-115.
56. Spradling, A., Fuller, M. T., Braun, R. E., & Yoshida, S. (2011). Germline stem cells. Cold Spring Harbor Perspectives in Biology, 3(11), a002642. doi: 10. 1101/cshperspect. a002642.
57. Audet, J., Miller, C. L., Eaves, C. J., & Piret, J. M. (2002). Common and distinct features of cytokine effects on hematopoietic stem and progenitor cells revealed by dose-response surface analysis. Biotechnology and Bioengineering, 80, 393-404.
58. Zandstra, P. W., Conneally, E., Petzer, A. L., Piret, J. M., & Eaves, C. J. (1997). Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proceedings of the National Academy of Sciences of the United States of America, 94, 4698-4703.
59. Miller, C. L., Rebel, V. I., Lemieux, M. E., Helgason, C. D., Lansdorp, P. M., & Eaves, C. J. (1996). Studies of W mutant mice provide evidence for alternate mechanisms capable of activating hematopoietic stem cells. Experimental Hematology, 24, 185-194.
60. Ikuta, K., & Weissman, I. L. (1992). Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation. Proceedings of the National Academy of Sciences of the United States of America, 89, 1502-1506.
61. Bowie, M. B., Kent, D. G., Copley, M. R., & Eaves, C. J. (2007). Steel factor responsiveness regulates the high self-renewal phenotype of fetal hematopoietic stem cells. Blood, 109, 5043-5048.
62. Bowie, M. B., Kent, D. G., Dykstra, B., McKnight, K. D., McCaffrey, L., Hoodless, P. A., et al. (2007). Identification of a new intrinsically timed developmental checkpoint that reprograms key hematopoietic stem cell properties. Proceedings of the National Academy of Sciences of the United States of America, 104, 5878-5882.
63. Mendoza-Rincon, J. F., González-Robles, A., Lopez-Marure, R., & Caceres-Cortes, J. R. (2010). Enhanced activity of pSTAT-3 Ser-727 in functional endothelial cells under calcifying conditions. Current Chemical Biology, 4, 133-144.
64. Willems, L., Chapuis, N., Puissant, A., Maciel, T. T., Green, A. S., Jacque, N., et al. (2011). The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia, 26(6), 1195-1202. doi: 10. 1038/leu. 2011. 339.
65. Yang, Z. J., Chee, C. E., Huang, S., & Sinicrope, F. A. (2011). The role of autophagy in cancer: therapeutic implications. Molecular Cancer Therapeutics, 10, 1533-1541.